Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes [0.03%]
BARCODE2研究中转移性去势抵抗性前列腺癌男性患者的系谱测序揭示DNA修复基因中有广泛的致病突变
Sarah Benafif,Ann-Britt Jones,Susan Merson et al.
Sarah Benafif et al.
Background: The presence of germline mutations plays an increasingly important role in risk assessment and treatment of prostate cancer (PrCa). Screening for high-risk mutations in subsets of patients is becoming routine....
Hereditary gastrointestinal polyposis syndromes Rare Disease Collaborative Network consensus statement agreed at the RDCN meeting Birmingham 17th February 2022 [0.03%]
2022年2月17日在伯明翰举行的罕见病协作网络会议上达成共识声明：遗传性胃肠道息肉综合征
Susan Clark,Vicky Cuthill,Jackie Hawkins et al.
Susan Clark et al.
Estimating cure proportion in cancer clinical trials using flexible parametric cure models [0.03%]
基于灵活的参数治愈模型估计癌症临床试验中的治愈率
Yuka Sano,Shiro Tanaka,Tosiya Sato
Yuka Sano
Background: In the context of survival analysis in recent cancer clinical trials, there has been an increasing interest in the proportion of patients who are not susceptible to the event, known as the cure proportion. To ...
Spatial functional mapping of hypoxia inducible factor heterodimerisation and immune checkpoint regulators in clear cell renal cell carcinoma [0.03%]
透明细胞肾细胞癌中低氧诱导因子异二聚体和免疫检查点调节剂的空间功能图谱映射
Elena Safrygina,Christopher Applebee,Alan McIntyre et al.
Elena Safrygina et al.
Background: Clear cell renal cell carcinoma (ccRCC) is a highly malignant subtype of kidney cancer. Ninety percent of ccRCC have inactivating mutations of VHL that stabilise transcription factors, HIF1α and HIF2α, only ...
Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit [0.03%]
关于177卢茨尤姆PSMA-617注册研究的设计问题，这些偏差使得实验组结果偏向于与真正患者获益相背离的当代肿瘤学试验越来越不符合实际情况
J B Schnog,A J Duits,M J Samson
J B Schnog
In the PSMAfore randomized controlled trial patients with chemotherapy naïve castrate resistant metastasized prostate cancer (CRPC) progressing after one line of a second-generation androgen receptor signaling inhibitor (ARSI) were randomi...
Characterizing functional DNA damage and response caused by the combination of CHK1 and WEE1 inhibitors in ovarian and breast cancer models [0.03%]
卵巢癌和乳腺癌模型中联合使用CHK1和WEE1抑制剂引起的功能性DNA损伤和反应的特征分析
Adam Stewart,Jiin Song,Lisa Pickard et al.
Adam Stewart et al.
Background: We proposed to quantify reduction of functional DNA damage response (DDR) mechanisms caused by the combination of CHK1 and WEE1 inhibitors. Me...
Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle [0.03%]
肠道微生物组和营养相关免疫疗法响应预测因子：解开谜题
Cecilia Hes,R Thomas Jagoe
Cecilia Hes
The gut microbiome is emerging as an important predictor of response to immune checkpoint inhibitor (ICI) therapy for patients with cancer. However, several nutrition-related patient characteristics, which are themselves associated with cha...
Ronit Juthani,Sachin Punatar,Indraneel Mittra
Ronit Juthani
Most patients with cancer receive chemotherapy. Unfortunately, chemotherapy is associated with a number of potentially life-threatening side effects. There is a need to ameliorate chemotoxicity to improve therapeutic outcomes and quality of...
High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids [0.03%]
高剂量短期奥希替尼治疗患者衍生的转移性结直肠癌类器官有效
Kirti K Iyer,Dennis Poel,Anne Miggelenbrink et al.
Kirti K Iyer et al.
Background: Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs have, high-dose regimens that tri...
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses [0.03%]
伊沙匹隆联合贝伐单抗治疗铂耐药或难治性卵巢、输卵管和原发性腹膜癌Ⅱ期随机试验（NCT03093155）：生存分析及亚组分析更新结果
Dana M Roque,Eric R Siegel,Natalia Buza et al.
Dana M Roque et al.
Background: Ixabepilone may retain activity in paclitaxel-resistant disease. We previously reported improved response rates (ORR), progression-free (PFS), and overall survival (OS) conferred by ixabepilone+bevacizumab (IX...